Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
09
03
2022
accepted:
26
05
2022
revised:
11
05
2022
pubmed:
7
6
2022
medline:
9
9
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is one of auto-immune antibodies which is associated with a rare subtype of dermatomyositis (DM), and MDA5-DM is well-characterized by rapid progressive interstitial lung disease (ILD) which in part resembles pulmonary complications after allogeneic hematopoietic cell transplantation (allo-HCT). However, previous studies about anti-MDA5 antibody after allo-HCT were extremely limited. Here, we present 4 cases of ILD with anti-MDA5 antibody after allo-HCT. All of the cases showed rapidly progressive clinical course and 3 of 4 cases died despite intensive immunosuppressive therapies which included prednisolone, cyclophosphamide and calcineurin inhibitor. Additionally, 3 of 4 cases had tested positive for anti-MDA5 antibody by using cryopreserved plasma which were collected about 2-3 months before the diagnosis of MDA5-DM-ILD. It suggests that an inflammatory condition due to MDA5-DM-ILD might have sub-clinically occurred before the development of respiratory failure. The current cases suggest that the clinical feature was relatively similar to classical MDA5-DM-ILD, although it is difficult to distinguish MDA5-DM-ILD from chronic GVHD and other pulmonary complications after allo-HCT. Since clinical courses of MDA5-DM-ILD is considerably aggressive, it is important to discriminate MDA5-DM-ILD from other complications after allo-HCT.
Identifiants
pubmed: 35661835
doi: 10.1038/s41409-022-01730-6
pii: 10.1038/s41409-022-01730-6
pmc: PMC9166177
doi:
Substances chimiques
Autoantibodies
0
Interferon-Induced Helicase, IFIH1
EC 3.6.4.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1382-1388Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Bergeron A, Chevret S, Peffault de Latour R, Chagnon K, de Margerie-Mellon C, Rivière F, et al. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J. 2018;51. https://doi.org/10.1183/13993003.02617-2017
Broglie L, Fretham C, Al-Seraihy A, George B, Kurtzberg J, Loren A, et al. Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2019;25:2024–30. https://doi.org/10.1016/j.bbmt.2019.06.004 .
doi: 10.1016/j.bbmt.2019.06.004
Hakim A, Cooke KR, Pavletic SZ, Khalid M, Williams KM, Hashmi SK. Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transpl. 2019;54:383–92. https://doi.org/10.1038/s41409-018-0266-6 .
doi: 10.1038/s41409-018-0266-6
Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;28:425–34. https://doi.org/10.1038/sj.bmt.1703142 .
doi: 10.1038/sj.bmt.1703142
Zhang Z, Wang C, Peters SG, Hogan WJ, Hashmi SK, Litzow MR, et al. Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. Chest. 2021;159:2325–33. https://doi.org/10.1016/j.chest.2021.01.008 .
doi: 10.1016/j.chest.2021.01.008
pubmed: 33434501
Adachi Y, Ozeki K, Ukai S, Sagou K, Fukushima N, Kohno A. Patterns of onset and outcome of cryptogenic organizing pneumonia after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2019;109:700–10. https://doi.org/10.1007/s12185-019-02643-9 .
doi: 10.1007/s12185-019-02643-9
pubmed: 30972616
Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011;183:1262–79. https://doi.org/10.1164/rccm.2007-413ST .
doi: 10.1164/rccm.2007-413ST
pubmed: 21531955
pmcid: 3266140
Seo S, Renaud C, Kuypers JM, Chiu CY, Huang ML, Samayoa E, et al. Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies. Blood. 2015;125:3789–97. https://doi.org/10.1182/blood-2014-12-617035 .
doi: 10.1182/blood-2014-12-617035
pubmed: 25918347
pmcid: 4463739
Brownback KR, Frey JW, Abhyankar S. Bronchoscopic features, associations, and outcomes of organizing pneumonia following allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2019;98:2187–95. https://doi.org/10.1007/s00277-019-03746-3 .
doi: 10.1007/s00277-019-03746-3
pubmed: 31273420
pmcid: 7080065
Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6. https://doi.org/10.1002/art.21023 .
doi: 10.1002/art.21023
pubmed: 15880816
Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193–2200. https://doi.org/10.1002/art.24621 .
doi: 10.1002/art.24621
pubmed: 19565506
Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatol (Oxf). 2010;49:433–40. https://doi.org/10.1093/rheumatology/kep375 .
doi: 10.1093/rheumatology/kep375
Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, et al. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clin Rev Allergy Immunol. 2021;60:293–304. https://doi.org/10.1007/s12016-020-08822-5 .
doi: 10.1007/s12016-020-08822-5
pubmed: 33405101
Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatol (Oxf). 2012;51:1278–84. https://doi.org/10.1093/rheumatology/ker518 .
doi: 10.1093/rheumatology/ker518
Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol (Oxf). 2012;51:1563–70. https://doi.org/10.1093/rheumatology/kes102 .
doi: 10.1093/rheumatology/kes102
Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. 2020;72:488–98. https://doi.org/10.1002/art.41105 .
doi: 10.1002/art.41105
pubmed: 31524333
Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatol (Oxf). 2020;59:3284–92. https://doi.org/10.1093/rheumatology/keaa123 .
doi: 10.1093/rheumatology/keaa123
Lepelletier C, Bengoufa D, Lyes Z, de Masson A, Chasset F, Jachiet M, et al. Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Dermatol. 2017;153:184–8. https://doi.org/10.1001/jamadermatol.2016.3976 .
doi: 10.1001/jamadermatol.2016.3976
pubmed: 27851860
New-Tolley J, Smith C, Koszyca B, Otto S, Maundrell A, Bardy P, et al. Inflammatory myopathies after allogeneic stem cell transplantation. Muscle Nerve. 2018;58:790–5. https://doi.org/10.1002/mus.26341 .
doi: 10.1002/mus.26341
pubmed: 30194844
Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78:776–85. https://doi.org/10.1016/j.jaad.2017.12.010 .
doi: 10.1016/j.jaad.2017.12.010
pubmed: 29229575
Jiang L, Wang Y, Peng Q, Shu X, Wang G, Wu X. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin Rheumatol. 2019;38:1655–63. https://doi.org/10.1007/s10067-019-04457-w .
doi: 10.1007/s10067-019-04457-w
pubmed: 30739212
Lian X, Zou J, Guo Q, Chen S, Lu L, Wang R, et al. Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model. Chest. 2020;158:1535–45. https://doi.org/10.1016/j.chest.2020.04.057 .
doi: 10.1016/j.chest.2020.04.057
pubmed: 32428508
Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91–99. https://doi.org/10.1016/j.rmed.2016.10.019 .
doi: 10.1016/j.rmed.2016.10.019
pubmed: 27888997
Zuo Y, Ye L, Liu M, Li S, Liu W, Chen F, et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology. 2020;59:2829–37. https://doi.org/10.1093/rheumatology/keaa034 .
doi: 10.1093/rheumatology/keaa034
pubmed: 32065646
Zhou M, Ye Y, Yan N, Lian X, Bao C, Guo Q. Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis. Clin Rheumatol. 2020;39:1919–27. https://doi.org/10.1007/s10067-019-04918-2 .
doi: 10.1007/s10067-019-04918-2
pubmed: 31942657
Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, Ruiz-Rodríguez JC, Castellvi I, Rodriguez-Nieto MJ, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50:776–90. https://doi.org/10.1016/j.semarthrit.2020.03.007 .
doi: 10.1016/j.semarthrit.2020.03.007
pubmed: 32534273
Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N. Engl J Med. 2019;381:291–3. https://doi.org/10.1056/NEJMc1900045 .
doi: 10.1056/NEJMc1900045
pubmed: 31314977
Dias Junior AG, Sampaio NG, Rehwinkel J. A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation. Trends Microbiol. 2019;27:75–85. https://doi.org/10.1016/j.tim.2018.08.007 .
doi: 10.1016/j.tim.2018.08.007
pubmed: 30201512
Nishina N, Sato S, Masui K, Gono T, Kuwana M Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open. 2020;6. https://doi.org/10.1136/rmdopen-2020-001202
Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13:R214 https://doi.org/10.1186/ar3547 .
doi: 10.1186/ar3547
pubmed: 22192091
pmcid: 3334667
Yin X, Riva L, Pu Y, Martin-Sancho L, Kanamune J, Yamamoto Y, et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell Rep. 2021;34:108628 https://doi.org/10.1016/j.celrep.2020.108628 .
doi: 10.1016/j.celrep.2020.108628
pubmed: 33440148
pmcid: 7832566
Thorne LG, Reuschl AK, Zuliani-Alvarez L, Whelan MVX, Turner J, Noursadeghi M, et al. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. Embo J. 2021;40:e107826 https://doi.org/10.15252/embj.2021107826 .
doi: 10.15252/embj.2021107826
pubmed: 34101213
pmcid: 8209947
Sampaio NG, Chauveau L, Hertzog J, Bridgeman A, Fowler G, Moonen JP, et al. The RNA sensor MDA5 detects SARS-CoV-2 infection. Sci Rep. 2021;11:13638 https://doi.org/10.1038/s41598-021-92940-3 .
doi: 10.1038/s41598-021-92940-3
pubmed: 34211037
pmcid: 8249624
Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021;41:1021–36. https://doi.org/10.1007/s00296-021-04819-1 .
doi: 10.1007/s00296-021-04819-1
pubmed: 33774723
pmcid: 8000693
Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and Myositis: What We Know So Far. Curr Rheumatol Rep. 2021;23:63 https://doi.org/10.1007/s11926-021-01023-9 .
doi: 10.1007/s11926-021-01023-9
pubmed: 34216297
pmcid: 8254439
Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. 2020;56. https://doi.org/10.1183/13993003.01618-2020
Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012;64:3736–40. https://doi.org/10.1002/art.34657 .
doi: 10.1002/art.34657
pubmed: 22886382
Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. J Rheumatol. 2017;44:319–25. https://doi.org/10.3899/jrheum.160682 .
doi: 10.3899/jrheum.160682
pubmed: 28089977
Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176:395–402. https://doi.org/10.1111/bjd.14882 .
doi: 10.1111/bjd.14882
pubmed: 27452897